Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.77 |
| ▸ | CASP6 | P55212 | 20/20 | 0.77 |
| ▸ | CASP8 | Q14790 | 20/20 | 0.77 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495125 | 0.88 | CASP3 (0.69) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL18678078 | 0.86 | CASP3 (0.76) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL7199250 | 0.84 | CASP3 (0.77) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL8357263 | 0.82 | CASP3 (0.82) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL18850541 | 0.80 | CASP3 (1.00) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL7201957 | 0.80 | CASP3 (0.68) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL6831408 | 0.79 | CASP3 (0.50) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL18678037 | 0.79 | CASP3 (0.66) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL4556681 | 0.79 | CASP3 (0.61) | CASP3CASP6CASP8CASP7 | |
| SCHEMBL7277266 | 0.78 | CASP1 (0.64) | CASP3CASP6CASP8CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232788-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003072528-A2 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232788-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | CASP3 3/4885CASP6 26/4885CASP8 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.